医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GN MEDI Antibacterial Spray Launched to End COVID-19 Crisis and Solve the Shortage of Masks

2020年03月27日 PM09:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Ventex launched GN MEDI 99.9% antibacterial spray which is an eco-friendly and odorless product containing harmless minerals for sterilization and disinfection.

The product is developed by Ventex, a technology company that received IR52 Jang Young-shil Awards hosted by MSIT five times. Ventex received the awards in 2019, thanks to the antibacterial spray that featured the world’s first ‘coating technique with antibacterial mineral’.

GN MEDI 99.9% antibacterial spray eliminates 99.9 percent of pneumococcus, colon bacillus, and staphylococcus aureus. And Korea Testing & Research Institute checked that it sterilized 99.99 percent of Influenza A virus that is the same RNA virus family as COVID-19.

Nationally Authorized Testing- Inspection and Research Institute, KOTITI checked that the masks’ filters worked fine after spraying the antibacterial spray on KF94 masks. They checked filters’ functions under criteria, passing the amount of paraffin oil per minute following the test method of KF masks. It was widely known that KF94 masks usually prevent ninety-four percent.

When KOTITI tested pneumococcus after seventy-two hours from spraying the antibacterial spray on the mask, the mask had maintained 99.9 percent of excellent antibacterial function. The spray also eliminates the offensive smell.

Gyeongchan Go, President of Ventex said, “GN MEDI 99.9% antibacterial spray maintains the antibacterial effect for a long time compared to highly volatile ethanol and has an excellent safety unlike chlorine-releasing products causing cancers. Now you can use our spray that passed the skin irritation test for clothing and textile products as well as doorknobs, hand straps on the metro, and elevator buttons.”

The antibacterial spray is also used for sterilization, disinfection, and deodorization and acknowledged by KATRI that they fit for a stability standard of risk-concerned products. The safety test result will come out from U.S. Food and Drug Administration (FDA) during this month.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005109/en/

CONTACT

Ventex

Boram Jung

+82-70-4827-4877

bbo0026@gncos.co.kr

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
  • Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
  • Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
  • ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
  • ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial